Andrew A. Lane, MD, PhD

andrew lane

Dana-Farber Cancer Institute
Identifying vulnerabilities in hematologic malignancies driven by heterotrimeric G proteins

Blood cancers arise from cells that acquire mutations before becoming a leukemia. We study a gene called GNB1 that is often mutated in patients with "pre-leukemic" blood cells, and in leukemia and lymphoma. We will determine how best to target GNB1 mutant cells to treat and possibly prevent blood cancers.